|
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
However, across PSA cutoffs, MRI-TBx detected more prostate cancer than TRUS-Bx at PSA levels of 2.5 to <4 (29.5% vs. 56.6%; P < .001).
|
30415878 |
2019 |
|
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
The AUC-ROCs distinguishing nonprostate cancer vs prostate cancer, nonprostate cancer plus low Gleason Grade Group and low volume vs remaining prostate cancer with a higher Gleason Grade group or a higher volume on the PHI (Prostate Health Index) were significantly superior to the AUC-ROCs of prostate specific antigen and free-to-total prostate specific antigen.
|
31430244 |
2020 |
|
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
In a previous population-based study on 3369 European men with self-reported prostate cancer (PCa), it was shown that androgen receptor (AR) haplotype designated H2 was associated with high levels of serum PSA (prostate-specific antigen) concentration, and, at the same time, with low risk for PCa.
|
28176139 |
2017 |
|
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
In summary, the differences among the PCa/BPH/healthy control groups with respect to miR-320a/-b/-c levels in conjunction with higher levels in patients without a PSA relapse than in those with a relapse suggest the diagnostic potential of these miRNA-320 family members in PCa patients.
|
29535815 |
2018 |
|
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
A 75-year-old man who received a diagnosis of RCC in 2006 and prostate cancer in 2009 presented with elevated prostate-specific antigen levels (0.7 ng/mL) following prostatectomy.
|
28033223 |
2017 |
|
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Prostate cancer is usually diagnosed after the finding of a suspicious serum prostate-specific antigen level or digital rectal examination.
|
28473080 |
2017 |
|
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Regulation of prostate cancer cell growth and PSA expression by angiotensin II receptor blocker with peroxisome proliferator-activated receptor gamma ligand like action.
|
17440964 |
2007 |
|
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Positive predictive value analysis of prostate cancer was increased from 40% to 87.5% by integrating patient PSA blood levels with miR-21 and miR-141 profiles.
|
21345070 |
2011 |
|
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Our objective was to map the recurrence pattern of PCa early biochemical recurrence (BCR) after radical prostatectomy with <sup>68</sup>Ga-PSMA-11 PET/CT in patients with serum PSA levels of less than 1 ng/mL, determine how often consensus clinical target volumes (CTVs) based on the Radiation Therapy Oncology Group (RTOG) guidelines cover <sup>68</sup>Ga-PSMA-11 PET/CT-defined disease, and assess the potential impact of <sup>68</sup>Ga-PSMA-11 PET/CT on SRT.
|
29123013 |
2018 |
|
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
The PCA3 mRNA expression (PCA3/PSA mRNA) in the PCa group was significantly higher than that in the BPH group.
|
20970419 |
2011 |
|
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
In Asian patients with serum PSA levels between 4.0 and 20.0 ng/mL, 18-core biopsy was associated with superior clinical outcomes to those of 12-core biopsy for detecting prostate cancer.
|
30100355 |
2018 |
|
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Human prostate specific antigen (PSA) is expressed selectively in prostate epithelium and is a potential target for the immunotherapy against prostate cancer.
|
15651071 |
2005 |
|
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Irrespective of serum prostate-specific antigen level or Gleason score, the ratio between expression of MMPs and E-cadherin at the invasive edge of tumors exhibited the strongest association with nonorgan-confined prostate cancer.
|
10873080 |
2000 |
|
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
The expression of prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA) in 2,215 lymph nodes isolated from 120 patients with clinically localized prostate cancer was assessed by a fully quantitative real-time reverse transcriptase-PCR.
|
17317829 |
2007 |
|
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Prostate cancer (PCa) testing is currently based on measurement of serum prostate‑specific antigen levels and digital rectal examination, which are limited by a low predictive value and the adverse effects associated with overdiagnosis and overtreatment.
|
30483762 |
2019 |
|
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
The sensitivity of the nicotine- and PSA-specific GEMS devices matched the clinically relevant concentration ranges, and PSA-specific GEMS were able to detect pathological PSA levels in the serum of patients diagnosed with prostate cancer.
|
29686358 |
2018 |
|
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
In human prostate cancer cell line, LNCaP, PRE could reduce the cell growth, down-regulate the expression of AR and suppress prostate-specific antigen (PSA) secretion.
|
31489669 |
2019 |
|
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
The sensor responds to different levels of PSA in serum, correlating well with chemiluminescence ELISA used in hospitals even with higher potential to discriminate clinically meaningful prostate cancer.
|
30640124 |
2019 |
|
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
We examined the antitumor effect of suramin in an in vivo mouse model of hormone-refractory human prostate cancer to determine whether a decrease in PSA levels reflects a reduction in tumor growth (volume).
|
8637045 |
1996 |
|
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Importantly, sst1 action was also able to modulate androgen/AR activity, and reduced PSA secretion from PCa cell lines.
|
28905400 |
2017 |
|
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Our study has generated a detailed map of common genetic variation in the genomic region surrounding the KLK3 gene, which should be useful for fine-mapping the association signal as well as determining the contribution of this locus to prostate cancer risk and/or regulation of PSA expression.
|
19823874 |
2010 |
|
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Prostate cancer progression was defined as biochemical recurrence based on posttreatment prostate-specific antigen levels of >0.3 ng/mL for radical prostatectomy patients or a 2-ng/mL increase above the nadir for radiation therapy patients, initiation of hormone treatment, or metastases.
|
20651075 |
2010 |
|
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Studies have shown that supplementation of adult men with selenium-enriched yeast (SY) was protective against prostate cancer (PCa) and also reduced oxidative stress and levels of prostate-specific antigen.
|
20643827 |
2010 |
|
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
We tested whether a lycopene-rich tomato intervention could reduce the levels of prostate specific antigen (PSA) in prostate cancer patients.
|
27406859 |
2017 |
|
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
However, the specificity and sensitivity of serum prostate-specific antigen levels in PCa diagnosis are controversial.
|
28938548 |
2017 |